Register Login

KYVERNA THERAPEUTICS, INC. (KYTX)

(85% Positive) KYVERNA THERAPEUTICS, INC. (KYTX) Announces Enrollment Update for profile Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 20, 2026, 12:03 p.m.

    📋 KYVERNA THERAPEUTICS, INC. (KYTX) - Clinical Trial Update

    Filing Date: 2026-04-20

    Accepted: 2026-04-20 08:00:17

    Event Type: Clinical Trial Update

    Event Details:

    KYVERNA THERAPEUTICS, INC. (KYTX) Announces Clinical Trial Update KYVERNA THERAPEUTICS, INC. (KYTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: profile, Data
    • Diseases/Conditions: delivering durable, Chicago
    • Clinical Stage: Phase 3 trial, Phase 2
    • Collaboration: QMG
      • targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, miv-cel has potential to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases. About Kyverna TherapeuticsKyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. The Company’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its initial indications in stiff person syndrome and generalized myasthenia gravis. The Company is also advancing additional clinical and investigator-sponsored studies, including in multiple sclerosis and rheumatoid arthritis, to inform future priority indications and develop next-generation CAR T platforms to improve access and patient experience. For more information, please visit https://kyvernatx.com. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for the longer-term data from the Phase 2 portion of Kyverna’s KYSA-6 Phase 2/3 registrational trial of miv-cel to increase confidence in the Phase 3 portion of the trial and to reinforce miv-cel’s potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose, and the ability of such data to demonstrate continued deepening of response over time across multiple clinical outcome measures; Kyverna’s leadership in neuroimmunology CAR T; opportunities related to miv-cel, including its potential for outpatient administration and potential to set a new clinical standard, the ability of miv-cel to achieve MSE while eliminating the need for chronic immunotherapies following a single dose, and the potential for such achievement to represent a meaningful clinical advancement and to significantly improve daily function and quality of life for patients; the ability of miv-cel to target a disease at the source and to deeply deplete B-cells or drive an immune reset and achieve durable drug-free, disease-free remission for patients with gMG; the potential for miv-cel to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases, including to change the treatment paradigm for gMG with a single dose; the ongoing Phase 3 portion of the trial, including enrollment therein; Kyverna’s advancement of its potentially first-in-class neuroimmunology franchise with its initial indications in SPS and gMG and of additional clinical and investigator-sponsored studies, and the potential for such advancement to improve access and patient experience; and the anticipated timing for Kyverna’s conference call and webcast and presentations at the AAN Annual Meeting and the topics expected to be discussed during such conference call and webcast and presentations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; the possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission; intellectual property rights; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts: Investors: InvestorRelations@kyvernatx.com Media: media@kyvernatx.com 1Clinically meaningful improvements in MG-ADL and QMG are defined as a ≥2-point reduction in MG- ADL from baseline and a ≥3-point reduction in QMG from baseline.2 A clinically meaningful improvement in MGC is defined as ≥3-point reduction from baseline.3 Claytor B, et al. Muscle Nerve. 2023

    🔬 Clinical Development Pipeline (KYVERNA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Standard of Care Treatment DRUG Phase PHASE2 Myasthenia Gravis ClinicalTrials.gov
    KYV-101 BIOLOGICAL Phase PHASE2 Myasthenia Gravis ClinicalTrials.gov
    Standard lymphodepletion regimen DRUG Phase PHASE2 Myasthenia Gravis ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: KYVERNA THERAPEUTICS, INC.
    • Ticker Symbol: KYTX

Search

News categories